IDH1 mutation inhibits differentiation of astrocytes and glioma cells with low oxoglutarate dehydrogenase expression by disturbing α-ketoglutarate-related metabolism and epigenetic modification

Abstract

Isocitrate dehydrogenase (IDH) mutations frequently occur in lower-grade gliomas and secondary glioblastomas. Mutant IDHs exhibit a gain-of-function activity, leading to the production of D-2-hydroxyglutarate (D-2HG) by reducing α-ketoglutarate (α-KG), a central player in metabolism and epigenetic modifications. However, the role of α-KG homeostasis in IDH-mutated gliomagenesis remains elusive. In this study, we found that low expression of oxoglutarate dehydrogenase (OGDH) was a common feature in IDH-mutated gliomas, as well as in astrocytes. This low expression of OGDH resulted in the accumulation of α-KG and promoted astrocyte maturation. However, IDH1 mutation significantly reduced α-KG levels and increased glutaminolysis and DNA/histone methylation in astrocytes. These metabolic and epigenetic alterations inhibited astrocyte maturation and led to cortical dysplasia in mice. Moreover, our results also indicated that reduced OGDH expression can promote the differentiation of glioma cells, while IDH1 mutations impeded the differentiation of glioma cells with low OGDH by reducing the accumulation of α-KG and increasing glutaminolysis. Finally, we found that L-glutamine increased α-KG levels and augmented the differentiation-promoting effects of AGI5198, an IDH1-mutant inhibitor, in IDH1-mutant glioma cells. Collectively, this study reveals that low OGDH expression is a crucial metabolic characteristic of IDH-mutant gliomas, providing a potential strategy for the treatment of IDH-mutant gliomas by targeting α-KG homeostasis.

Keywords

α-ketoglutarate / IDH1 mutation / OGDH / L-glutamine / gliomas

References

[1] Pirozzi CJ , Yan H . The implications of IDH mutations for cancer development and therapy. Nat Rev Clin Oncol 2021; 18: 645- 61.

[2] Christensen BC , Smith AA , Zheng SC et al. DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 2011; 103: 143- 53.

[3] Figueroa ME , Abdel-Wahab O , Lu C et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553- 67.

[4] Turcan S , Rohle D , Goenka A et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483: 479- 83.

[5] Lu C , Ward PS , Kapoor GS et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012; 483: 474- 8.

[6] Coloff JL , Murphy JP , Braun CR et al. Differential glutamate metabolism in proliferating and quiescent mammary epithelial cells. Cell Metab 2016; 23: 867- 80.

[7] Tönjes M , Barbus S , Park YJ et al. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wildtype IDH1. Nat Med 2013; 19: 901- 8.

[8] Yudkoff M . Interactions in the metabolism of glutamate and the branched-chain amino acids and ketoacids in the CNS. Neurochem Res 2017; 42: 10- 8.

[9] Koivunen P , Lee S , Duncan CG et al. Transformation by the R-enantiomer of 2-hydroxyglutarate linked to EglN activation. Nature 2012; 483: 484- 8.

[10] Losman JA , Looper RE , Koivunen P et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013; 339: 1621- 5.

[11] Baksh SC , Finley LWS . Metabolic coordination of cell fate by α-ketoglutarate-dependent dioxygenases. Trends Cell Biol 2021; 31: 24- 36.

[12] Andersen JV , Schousboe A , Verkhratsky A . Astrocyte energy and neurotransmitter metabolism in Alzheimer’s disease: integration of the glutamate/GABA-glutamine cycle. Prog Neurobiol 2022; 217: 102331.

[13] Sperringer JE , Addington A , Hutson SM . Branched-chain amino acids and brain metabolism. Neurochem Res 2017; 42: 1697- 709.

[14] Dienel GA . Astrocytic energetics during excitatory neurotransmission: what are contributions of glutamate oxidation and glycolysis? Neurochem Int 2013; 63: 244- 58.

[15] Martin M , Portais JC , Labouesse J et al. [1-¹³C]Glucose metabolism in rat cerebellar granule cells and astrocytes in primary culture. Evaluation of flux parameters by ¹³C- and ¹H-NMR spectroscopy. Eur J Biochem 1993; 217: 617- 25.

[16] Hassel B , Bachelard H , Jones P et al. Trafficking of amino acids between neurons and gliain vivo. Effects of inhibition of glial metabolism by fluoroacetate. J Cereb Blood Flow Metab 1997; 17: 1230- 8.

[17] Hassel B , Sonnewald U , Fonnum F . Glial-neuronal interactions as studied by cerebral metabolism of [2-¹³C]acetate and [1-¹³C] glucose: an ex vivo ¹³C NMR spectroscopic study. J Neurochem 1995; 64: 2773- 82.

[18] Rothe F , Brosz M , Storm-Mathisen J . Quantitative ultrastructural localization of glutamate dehydrogenase in the rat cerebellar cortex. Neuroscience 1994; 62: 1133- 46.

[19] Spanaki C , Zaganas I , Kleopa KA et al. Human GLUD2 glutamate dehydrogenase is expressed in neural and testicular supporting cells. J Biol Chem 2010; 285: 16748- 56.

[20] Schousboe A , Waagepetersen HS , Sonnewald U . Astrocytic pyruvate carboxylation: status after 35 years. J Neurosci Res 2019; 97: 890- 6.

[21] Chen RH , Nishimura MC , Kharbanda S et al. Hominoid-specific enzyme GLUD2 promotes growth of IDH1^R132H glioma. Proc Natl Acad Sci USA 2014; 111: 14217- 22.

[22] Seltzer MJ , Bennett BD , Joshi AD et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010; 70: 8981- 7.

[23] McBrayer SK , Mayers JR , DiNatale GJ et al. Transaminase inhibition by 2-hydroxyglutarate impairs glutamate biosynthesis and redox homeostasis in glioma. Cell 2018; 175: 101- 16.e25.

[24] Chinopoulos C . Which way does the citric acid cycle turn during hypoxia? The critical role of α-ketoglutarate dehydrogenase complex. J Neurosci Res 2013; 91: 1030- 43.

[25] Mellinghoff IK , van den Bent MJ , Blumenthal DT et al. Vorasidenib in IDH1-or IDH2-mutant low-grade glioma. N Engl J Med 2023; 389: 589- 601.

[26] Yan H , Williams Parsons D , Jin G et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765- 73.

[27] Brat DJ , Verhaak RGW , Salama SR et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 2015; 372: 2481- 98.

[28] Horbinski C , Berger T , Packer RJ et al. Clinical implications of the 2021 edition of the WHO classification of central nervous system tumours. Nat Rev Neurol 2022; 18: 515- 29.

[29] Dolgin E . IDH inhibitors target common glioma mutation. Cancer Discov 2019; 9: 992.

[30] Sperringer JE , Addington A , Hutson SM . Branched-chain amino acids and brain metabolism. Neurochem Res 2017; 42: 1697- 709.

[31] TeSlaa T , Chaikovsky AC , Lipchina I et al. α-Ketoglutarate accelerates the initial differentiation of primed human pluripotent stem cells. Cell Metab 2016; 24: 485- 93.

[32] Tischler J , Gruhn WH , Reid J et al. Metabolic regulation of pluripotency and germ cell fate through α-ketoglutarate. EMBO J 2019; 38: e99518.

[33] Snezhkina AV , Krasnov GS , Zaretsky AR et al. Differential expression of alternatively spliced transcripts related to energy metabolism in colorectal cancer. BMC Genomics 2016; 17: 1011.

[34] Zhang Y , Chen M , Liu M et al. Glycolysis-related genes serve as potential prognostic biomarkers in clear cell renal cell carcinoma. Oxid Med Cell Longevity 2021; 2021: 6699808.

[35] Bunik V , Mkrtchyan G , Grabarska A et al. Inhibition of mitochondrial 2-oxoglutarate dehydrogenase impairs viability of cancer cells in a cell-specific metabolism-dependent manner. Oncotarget 2016; 7: 26400- 21.

[36] Vatrinet R , Leone G , De Luise M et al. The α-ketoglutarate dehydrogenase complex in cancer metabolic plasticity. Cancer Metab 2017; 5: 3.

[37] Wu N , Yang MY , Gaur U et al. Alpha-Ketoglutarate: physiological functions and applications. Biomol Ther 2016; 24: 1- 8.

[38] Burr SP , Costa ASH , Grice GL et al. Mitochondrial protein lipoylation and the 2-oxoglutarate dehydrogenase complex controls HIF1α stability in aerobic conditions. Cell Metab 2016; 24: 740- 52.

[39] Allen EL , Ulanet DB , Pirman D et al. Differential aspartate usage identifies a subset of cancer cells particularly dependent on OGDH. Cell Rep 2016; 17: 876- 90.

[40] Morris JP , Yashinskie JJ , Koche R et al. α-Ketoglutarate links p53 to cell fate during tumour suppression. Nature 2019; 573: 595- 9.

[41] Valor LM , Hervás-Corpión I . The epigenetics of glioma stem cells: a brief overview. Front Oncol 2020; 10: 602378.

[42] Crocker SJ , Frausto RF , Lindsay Whitton J et al. A novel method to establish microglia-free astrocyte cultures: comparison of matrix metalloproteinase expression profiles in pure cultures of astrocytes and microglia. Glia 2008; 56: 1187- 98.

[43] Ye D , Guan KL , Xiong Y . Metabolism, activity, and targeting of D- and L-2-hydroxyglutarates. Trends Cancer 2018; 4: 151- 65.

[44] Bardella C , Al-Dalahmah O , Krell D et al. Expression of Idh^1R132H in the murine subventricular zone stem cell niche recapitulates features of early gliomagenesis. Cancer Cell 2016; 30: 578- 94.

[45] Pirozzi CJ , Carpenter AB , Waitkus MS et al. Mutant IDH1 disrupts the mouse subventricular zone and alters brain tumor progression. Mol Cancer Res 2017; 15: 507- 20.

[46] Yanchus C , Drucker KL , Kollmeyer TM et al. A noncoding singlenucleotide polymorphism at 8q24 drives IDH1-mutant glioma formation. Science 2022; 378: 68- 78.

RIGHTS & PERMISSIONS

2024 The Author(s) 2024. Published by Oxford University Press on behalf of Higher Education Press.